• Faeth Therapeutics will present PK/PD modeling for its oral PI3K/AKT/mTOR inhibitor combination PIKTOR at STOP Cancer on Aug. 8.
• The analysis supported dose selection for the ongoing Phase 2 FTH-PIK-201 trial in second-line advanced endometrial cancer.
• The work points to a recommended Phase 2 regimen intended to balance pathway inhibition with tolerability, without reporting clinical efficacy outcomes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Faeth Therapeutics Inc published the original content used to generate this news brief via Business Wire (Ref. ID: 20260807091302) on August 07, 2026, and is solely responsible for the information contained therein.